Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Pharmacists Have Solutions To Help Address Recommendations In The Leaders' Project Health Care Reform Report
The American Pharmacists Association (APhA) applauds the recommendations regarding chronic disease in the report by the Bipartisan Policy Center"s (BPC) Leaders" Project, entitled "Crossing Our Lines: Working Together to Reform the U.S. Health System." The report outlines key health care reform policy recommendations from a bipartisan perspective to ensure that all Americans have quality, affordable health care.
generic viagra online
Stanford Bioethicist And Colleagues Call For Federal Regulation Of Genetic Ancestry Testing
Imagine donating a sample of your DNA to help researchers study the genetics of diabetes. The disease is common among your friends and family, and you"re proud of your role in finding out why. Now, imagine that some time later, you learn that your DNA has been used for other studies on topics you never expected - schizophrenia, human migration, inbreeding. Although your name isn"t attached to the sample anymore, scientists are using your DNA to draw conclusions about your community and your ancestors. Some of these studies violate your cultural beliefs.
plastic surgery before after
News of the day
Racial Disparities In Breast Cancer Mortality Are Not Driven By Estrogen Receptor Status Alone
Black women who are diagnosed with breast cancer have a higher probability of dying from the disease than white women, regardless of their estrogen receptor status, according to research from the National Cancer Institute (NCI), part of the National Institutes of Health. Differences in breast cancer mortality may reflect racial differences in access and response to innovative breast cancer treatments, as well as other biological and non-biological factors, according to the report. In addition, the researchers found that differences in outcomes in the first few years post-diagnosis make up nearly all of the disparity. These results were published online July 7, 2009 in the Journal of the National Cancer Institute.
Nutrition

BioElectronics Announces Pivotal Clinical Study On Musculoskeletal Disorders

BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, announced its sponsorship of a groundbreaking clinical study on musculoskeletal disorders. The randomized, double blinded and placebo-controlled study will be supervised by a primary investigator, Sheena Kong, MD of San Francisco, California in conjunction with several other leading physicians. "This is a very exciting field of research and we are looking forward to determining the safety and efficacy of BioElectronics Corporation"s ActiPatch for the treatment of many different types of musculoskeletal complaints," commented Dr. Kong. "Since my days studying at Harvard University I have been very interested in treatments such as Pulsed Electromagnetic Field therapy (PEMF) as an alternative to pharmaceuticals. We are currently in process of working with our Independent Review Board (IRB) and registering the study with the National Institutes of Health (NIH). Patient recruitment is expected to begin over the next few weeks. We believe this will be one of the largest studies ever completed on the subject of general muscular skeletal complaints." Andrew Whelan, CEO of BioElectronics Corp., added, "The sponsorship and completion of the study are significant events for our Company. While we are seeing success within the plastic surgery market and in our international distribution channels, we believe the U.S. markets for back, knee, foot/ankle, and elbow pain are our biggest opportunities. This study is specifically designed to allow us to apply to the U.S. Food and Drug Administration for an indication for pain relief for general muscular skeletal complaints. With the many concerns over the dangers of taking medications such as acetaminophen and NSAIDs, we believe U.S. consumers are looking for safer and more effective pain relief options. We believe our unique and patented drug-free technologies will effectively fill this need." The management team of BioElectronics will hold a conference call on Thursday, June 18 at 4:15 p.m. (EDT) to discuss this study and other ongoing clinical trials several of which are nearing conclusion. On the call Barry Eppley, M.D., D.M.D will discuss the recent clinical study on dysmenorrhea and Sheena Kong, MD will discuss the design of the musculoskeletal disorder study. To access the conference call, please dial 712-432-0080 approximately 10 minutes prior to the start time and enter access code 404367# to be placed into the conference. BioElectronics Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009